( November 6, 2025, 8:22 AM EST) -- SAN FRANCISCO — A federal judge in California granted a biopharmaceutical company’s motion to dismiss investors’ securities class action against it for allegedly failing to disclose the findings from clinical trials of its lead product candidate that, once revealed, caused the company’s stock to drop, holding that the risk disclosures were not inherently misleading even though they didn’t discuss the risks presented by the clinical trial findings....